Stockscreener 앱 받기
0.95
7.77%
-0.08
Clearside Biomedical Inc 주식(CLSD)의 최신 뉴스
Clearside Biomedical's SWOT analysis: innovative eye treatment stock faces pivotal trial - MSN
Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, - GlobeNewswire
China Opens Door to Revolutionary Eye Treatment: What Makes ARCATUS a Game-Changer in $1B+ Market? - StockTitan
Clearside Biomedical (NASDAQ:CLSD) Stock Price Crosses Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Clearside reports progress in wet AMD treatment trials - MSN
Clearside Biomedical Announces Additional Data from the - GlobeNewswire
Clearside reports progress in wet AMD treatment trials By Investing.com - Investing.com Nigeria
Clearside's Eye Treatment Breakthrough: 6-Month Freedom from Injections for Majority of AMD Patients - StockTitan
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives $5.33 Average Price Target from Analysts - MarketBeat
Selling Your Clearside Biomedical Inc (CLSD) Stock? Here’s What You Need To Know - Stocks Register
Clearside Biomedical (NASDAQ:CLSD) Share Price Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference - The Manila Times
Clearside Biomedical to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference - Nasdaq
Clearside Biomedical to Participate in Fireside Chat at the - GlobeNewswire
Inside Clearside Biomedical's Strategic Vision: CEO Fireside Chat at Major Healthcare Conference - StockTitan
Clearside Biomedical Highlights CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial at Upcoming Conferences - Nasdaq
Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program - GlobeNewswire
Clearside Biomedical Announces Multiple Medical Meeting - GlobeNewswire
Revolutionary Eye Treatment Could Replace Monthly Injections for AMD Patients - StockTitan
Assenagon Asset Management S.A. Sells 125,190 Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) - Defense World
Clearside Biomedical (NASDAQ:CLSD) Stock Price Passes Below 50 Day Moving AverageWhat's Next? - MarketBeat
Clearside Biomedical (CLSD) Stock Price, News & Analysis - MarketBeat
Clearside Biomedical Announces its Asia-Pacific Partner, - GlobeNewswire
Clearside's ARCATUS Eye Treatment Wins Historic First Approvals in Australia, Singapore - StockTitan
Clearside Biomedical, Inc. (NASDAQ:CLSD) Sees Significant Decline in Short Interest - MarketBeat
Geode Capital Management LLC Buys 59,089 Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) - Defense World
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of “Buy” by Analysts - Defense World
Clearside Biomedical (NASDAQ:CLSD) Stock Price Crosses Below 50-Day Moving Average – Here’s Why - Defense World
Clearside Biomedical (NASDAQ:CLSD) Shares Pass Below 50 Day Moving AverageWhat's Next? - MarketBeat
Further weakness as Clearside Biomedical (NASDAQ:CLSD) drops 14% this week, taking five-year losses to 72% - Simply Wall St
Clearside Biomedical stock hits 52-week low at $0.92 By Investing.com - Investing.com South Africa
Clearside Biomedical stock hits 52-week low at $0.92 - Investing.com
Clearside announces publication of insights on drug development, regulation - Yahoo Finance
Analyst Sees 500% Upside for This Pharmaceutical Penny Stock - GuruFocus.com
Clearside Biomedical Announces Publication of Critical - GlobeNewswire
Clearside Biomedical Unveils Groundbreaking Insights on Retinal Drug Development in Eye Journal - StockTitan
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Brokerages Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Price Target at $5.33 - MarketBeat
Here's Why Clearside Biomedical (CLSD) Is a Great 'Buy the Bottom' Stock Now - MSN
Clearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Down 11.8% in November - MarketBeat
0.27%
3.05%
자본화:
|
볼륨(24시간):